Several small molecule inhibitors of PIM kinases are currently in clinical development [191, 201] and some of them showed synthetic lethality with MYC and synergy with anti‐CD20 immunotherapy in preclinical models of MYC‐driven TNBC and DLBCL, respectively [202, 203]. Here, MYC is linked to diffuse large B-cell lymphoma.